COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk

on Wednesday reported third-quarter sales growth of

11%, in line with forecasts, as the Danish drugmaker's new CEO

pushes a deep restructuring drive to claw back lost ground in a

fierce obesity drug market battle.

The Danish company said it lowered its full-year profit

forecast, while also lowering the top end of its full-year sales

forecast range.

The rise in sales in local currency terms, which has slowed

sharply in the last year as competition has risen from rival Eli

Lilly ( LLY ) and copycat treatments, compared with 11.4% growth

expected by analysts in a company-compiled consensus.

Novo shot to become Europe's most valuable firm on the back

of rapid sales growth of its blockbuster obesity drug Wegovy,

but has seen sales growth slow, sparking a management overhaul

and dragging down its share price.